Table 5.
Characteristics of Randomized Clinical Trials by Reporting Adequacy (Drug Group)
| Characteristic | Adequate reporting, No. (%) | Inadequate reporting, No. (%) | Total, No. (%) | P |
|---|---|---|---|---|
| Time of registration | ||||
| 2003–2013.06 | 29 (67.44) | 30 (76.92) | 59 (71.95) | 0.340 |
| 2013.06–2023 | 14 (32.56) | 9 (23.08) | 23 (28.05) | |
| Primary purpose | ||||
| Treatment | 42 (97.67) | 32 (82.05) | 74 (90.24) | 0.028* |
| Other | 1 (2.33) | 6 (15.38) | 7 (8.54) | |
| Prevent | 0 (0.00) | 1 (2.56) | 1 (1.22) | |
| Intervention model | ||||
| Crossover | 3 (6.98) | 10 (25.64) | 13 (15.85) | 0.030* |
| Parallel | 39 (90.70) | 29 (74.36) | 68 (82.93) | |
| Factorial | 1 (2.33) | 0 (0.00) | 1 (1.22) | |
| Arm | ||||
| 2 | 31 (72.09) | 31 (79.49) | 62 (75.61) | 0.371 |
| 3 | 9 (20.93) | 8 (20.51) | 17 (20.73) | |
| ≥4 | 3 (6.98) | 0 (0.00) | 3 (3.66) | |
| Blinding | ||||
| None or open label | 11 (25.58) | 10 (25.64) | 21 (25.61) | 0.923 |
| Single | 1 (2.33) | 2 (5.13) | 3 (3.66) | |
| Double or more | 31 (72.09) | 27 (69.23) | 58 (70.73) | |
| Funder type | ||||
| None or departmental | 17 (39.53) | 16(41.03) | 33(40.24) | 0.891 |
| Industry or other external | 26 (60.47) | 23(58.97) | 49(59.76) | |
| Recruitment | ||||
| Single center | 15 (34.88) | 12 (30.77) | 27 (32.93) | 0.817 |
| Multicenter | 28 (65.12) | 25 (64.10) | 53 (64.63) | |
| Missing | 0 (0.00) | 2 (5.13) | 2 (2.44) | |
| No. of participants | ||||
| <350 | 27 (62.79) | 22 (56.41) | 49 (59.76) | 0.556 |
| ≥350 | 16 (37.21) | 17 (43.59) | 33 (40.24) | |
| PI region | ||||
| Nonhigh SDI | 12 (27.91) | 7 (17.95) | 19 (23.17) | 0.286 |
| High SDI | 31 (72.09) | 32 (82.05) | 63 (76.83) | |
| PI region | ||||
| <90 | 40 (93.02) | 35 (89.74) | 75 (91.46) | 0.703 |
| ≥90 | 3 (6.98) | 4 (10.26) | 7 (8.54) | |
| PI region | ||||
| High income | 31 (72.09) | 34 (87.18) | 65 (79.27) | 0.092 |
| Nonhigh income | 12 (27.91) | 5 (12.82) | 17 (20.73) | |
| PI region | ||||
| North America | 13 (30.23) | 15 (38.46) | 28 (34.15) | 0.050* |
| Europe | 5 (11.63) | 11 (28.21) | 16 (19.51) | |
| Other | 25 (58.14) | 13 (33.33) | 38 (46.34) | |
*
P < 0.05